Biotech | August 08, 2022
Biocon Sdn. Bhd. enters Malaysia Book of Records
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Lacosamide Injection is used to treat partial-onset seizures.
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
The facility is among 12 centres established worldwide, and the first in Asia
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The drug is indicated for use in combination with other drugs
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
Subscribe To Our Newsletter & Stay Updated
